Key Takeaways
- • City Therapeutics raised $135 million in Series B funding led by John Maraganore, former CEO of Alnylam Pharmaceuticals, to advance a new generation of RNAi (RNA interference) therapeutics with improved delivery mechanisms and potency.
- • City aims to design smaller, more potent RNAi triggers capable of sparking mRNA cutting, positioning the company to expand RNAi applications beyond the liver-focused disease targets that have limited the field's current market reach.
- • An RNAi renaissance is underway with multiple well-funded startups—including City Therapeutics and Judo Bio (both debuting with $100M+ in funding), Switch Therapeutics, and Aro Biotherapeutics—signaling institutional and venture investor confidence in the technology's next phase.
- • Since 2018, six RNAi-based medicines have gained regulatory approval for rare diseases and high cholesterol; dozens more are in clinical testing, demonstrating commercial validation after two decades of development challenges centered on drug delivery.
- • Series B funding for biotech companies shows strong institutional interest, with CVC-backed rounds averaging $100M versus $40M for Series A, indicating premium valuations for companies with proven technical progress and experienced leadership.
Summary
City Therapeutics, a newly formed RNAi biotech company, has secured $135 million in Series B funding, marking a significant milestone in what industry observers describe as an RNAi renaissance. The company is led by John Maraganore, the former chief executive of Alnylam Pharmaceuticals—the field's best-known player—who now serves as City's executive chair. This funding round reflects renewed institutional confidence in RNA interference technology after decades of technical hurdles and limited clinical applications.
The company's core strategy centers on designing a new generation of RNAi therapeutics that are smaller and more potent than existing approaches. Unlike first-generation RNAi drugs that have been largely constrained to liver-focused disease targets, City aims to engineer RNAi triggers capable of broader tissue penetration and improved cellular delivery. This technological advancement addresses a fundamental limitation that has constrained RNAi's competitive position relative to emerging genetic medicines such as CRISPR, which offer longer-lasting therapeutic effects.
The funding announcement reflects a broader wave of RNAi-focused startups entering the market with substantial capital backing. In the same period, Judo Bio debuted with over $100 million in funding, while Switch Therapeutics and Aro Biotherapeutics completed significant private financings. This cluster of well-capitalized entrants suggests that fundamental technical barriers to RNAi delivery—which historically delayed the field's commercial development—have now been substantially overcome. The technology itself has established clinical proof of concept: since 2018, six RNAi-based medicines have won regulatory approval for rare diseases and elevated cholesterol, with dozens more in clinical testing.
The institutional capital flowing into RNAi startups reflects confidence in experienced leadership and demonstrated technical progress. Series B biotech funding data shows CVC-backed rounds averaging $100 million, compared to Series A median sizes of $40 million, indicating investor willingness to deploy significant capital when founding teams bring domain expertise and clear technical differentiation. Maraganore's involvement signals that the field's pioneers believe RNAi has entered a new phase capable of addressing therapeutic targets previously considered inaccessible to the platform.
The company's core strategy centers on designing a new generation of RNAi therapeutics that are smaller and more potent than existing approaches. Unlike first-generation RNAi drugs that have been largely constrained to liver-focused disease targets, City aims to engineer RNAi triggers capable of broader tissue penetration and improved cellular delivery. This technological advancement addresses a fundamental limitation that has constrained RNAi's competitive position relative to emerging genetic medicines such as CRISPR, which offer longer-lasting therapeutic effects.
The funding announcement reflects a broader wave of RNAi-focused startups entering the market with substantial capital backing. In the same period, Judo Bio debuted with over $100 million in funding, while Switch Therapeutics and Aro Biotherapeutics completed significant private financings. This cluster of well-capitalized entrants suggests that fundamental technical barriers to RNAi delivery—which historically delayed the field's commercial development—have now been substantially overcome. The technology itself has established clinical proof of concept: since 2018, six RNAi-based medicines have won regulatory approval for rare diseases and elevated cholesterol, with dozens more in clinical testing.
The institutional capital flowing into RNAi startups reflects confidence in experienced leadership and demonstrated technical progress. Series B biotech funding data shows CVC-backed rounds averaging $100 million, compared to Series A median sizes of $40 million, indicating investor willingness to deploy significant capital when founding teams bring domain expertise and clear technical differentiation. Maraganore's involvement signals that the field's pioneers believe RNAi has entered a new phase capable of addressing therapeutic targets previously considered inaccessible to the platform.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.